Global Nuclear Medicine Diagnostic (SPECT and PET) Market Report, History and Forecast 2016-2027, Breakdown Data by Manufacturers, Key Regions, Types and Application

The main difference between SPECT and PET scans is the type of radiotracers used. While SPECT scans measure gamma rays, the decay of the radiotracers used with PET scans produce small particles called positrons. A positron is a particle with roughly the same mass as an electron but oppositely charged.

Market Analysis and Insights: Global Nuclear Medicine Diagnostic (SPECT and PET) Market
In 2020, the global Nuclear Medicine Diagnostic (SPECT and PET) market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% between 2021 and 2027
Global Nuclear Medicine Diagnostic (SPECT and PET) Scope and Market Size
The global Nuclear Medicine Diagnostic (SPECT and PET) market is segmented by region (country), company, by Type, and by Application. Players, stakeholders, and other participants in the global Nuclear Medicine Diagnostic (SPECT and PET) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), byType, and by Application for the period 2016-2027.

Segment by Type
SPECT
PET

Segment by Application
Oncology
Cardiology
Neurology
Others

By Company
GE Healthcare
Siemens Healthineers
Philips Healthcare
Mediso
Spectrum Dynamics
Bruker
SurgicEye
MIE
MILabs

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Colombia
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE